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Background: Nasopharyngeal carcinoma (NPC) accounts for 0.6% of all cancers worldwide with the highest
prevalence in South East Asia, Southern China and Northern Africa but the disease is uncommon in Europe with an
annual incidence in this region of less than 1 per 100 000. Although the Epstein-Barr virus (EBV) is a well known
causative agent in NPC, recent reports have implicated oncogenic Human Papillomavirus (HPV) in a subgroup of
these tumours. The recent striking rise of oropharyngeal carcinoma has been attributed to HPV, but little is known
about the prevalence and clinical significance of the virus in NPC. The aim of this study was to determine the
prevalence of oncogenic HPV in NPC from tissue archives of two head and neck cancer centres in the UK.
Methods: Samples were available for 67 patients with clinically validated NPC. The detection of high-risk HPV was
carried out by screening all cases for p16 using immunohistochemistry and HPV DNA by polymerase chain reaction
(PCR) using GP5+/6+ primers. All cases with p16 over-expression or positive for HPV by PCR were then examined
by high-risk HPV DNA in-situ hybridisation and genotype analysis by PCR.
Results: Eleven cases (11/67, 16.4%) showed concurrent over-expression of p16 and evidence of high-risk HPV DNA
by in-situ hybridisation; the majority were HPV16 positive. Of these 11 cases, nine occurred in Whites and two in
Blacks. Histologically, there were two keratinising squamous cell carcinoma and nine non-keratinising carcinomas
(eight differentiated and one undifferentiated). None of the HPV-positive cases showed any co-infection with EBV.
There was no statistically significant difference in overall survival outcome between patients with HPV-positive and
HPV-negative NPC.
Conclusion: The results of this study show that oncogenic HPV is associated with a subgroup of NPCs and is more
likely to occur in Whites. However, unlike oropharyngeal carcinoma there was no significant difference in overall
survival between patients with HPV-positive and HPV-negative NPC.
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Table 1 Summary of patient and tumour characteristics
of all NPC cases

















Far Eastern Asian 17 (25.4)
Black 14 (20.9)
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Nasopharyngeal carcinoma (NPC) constitutes 0.6% of all
cancers worldwide but there is a wide geographic and
ethnic variation in the incidence rates of the disease [1].
For example, incidence rates of up to 30 per 100,000
have been reported in certain parts of China in contrast
to <1 per 100,000 in North America [2,3]. In the United
Kingdom, NPC is rare with a rate of 0.3-0.4 per 100,000
resulting in approximately 208 new cases per year [4].
The World Health Organisation (WHO) has classified
NPC according to histological criteria into keratinising
squamous cell carcinoma (KSCC, formerly WHO type I),
non-keratinising carcinoma differentiated type (NK-D,
formerly WHO type II), non-keratinising carcinoma undif-
ferentiated (NK-U, formerly WHO type III) and basaloid
squamous cell carcinoma (BSCC) [5]. The geographic and
ethnic variation of this disease is also reflected in the histo-
logical subtype where KSCCs comprise around 25% and
2% of NPCs in North America and Southern China, re-
spectively [6]. This disparity may be explained by differ-
ences in genetic and environmental factors.
Although the Epstein-Barr virus (EBV) has long been
implicated in nasopharyngeal carcinogenesis, increasing
numbers of reports have identified an association of
oncogenic human papillomavirus (HPV) in a sub-group
of NPCs [7-16]. Whilst HPV is now recognised as the
causative factor for the recent striking increase in squa-
mous cell carcinoma of the oropharynx in Europe and
North America, similar epidemiological trends have not
been observed in NPC [17]. Furthermore, little is known
about the prevalence of oncogenic HPV in NPC and its
clinical significance.
Therefore, the aim of this study was to determine the
incidence of oncogenic HPV in patients with NPC from
two head and neck cancer centres in the UK and to cor-
relate HPV status with patient ethnicity, histological
grade, EBV status and overall survival.
Results
Histological subtype
Of the 67 cases included in this study, there were 6
(8.9%) keratinising squamous cell carcinomas (KSCCs),
20 (29.9%) non-keratinising carcinomas, differentiated
type (NK-D), 40 (59.7%) non-keratinising carcinomas,
undifferentiated type (NK-U), and 1 (1.5%) was a basaloid
squamous cell carcinoma (BSCC, Table 1). There was a
statistically significant correlation between ethnicity (Far
Eastern Asians, p=0.01 Chi square) and histological sub-
type (NK-U, p <0.001 Chi square).
EBV status
Forty-seven (70.1%) were positive for EBV. Of these 17
(36.2%), 16 (34.0%), 12 (25.3%) and 2 (4.2%) occurred in
Whites, Far Eastern Asians, Blacks and North Africans,respectively. One (2.1%) was a KSCC, 36 (76.6%) were
NK-Us, 9 (19.2%) were NK-Ds, and 1 (2.1%) was a BSCC.
HPV status
Eleven (16.4%) cases demonstrated p16 over-expression,
all of which were assigned a maximum H score of
300 (staining intensity × percentage tumour staining;
3×100=300) [18]. All cases over-expressing p16 were also
positive for HPV DNA by consensus PCR and ISH for
high-risk types. Among the 56 p16-negative cases, 51 had
sufficient FFPE tissue for DNA extraction and amplifiable
DNA was present in 40 of 51 samples. Two of these 40
cases were positive for HPV DNA by PCR, but were sub-
sequently negative for high-risk HPV ISH. Of the HPV-
positive NPCs, all were negative for EBV; 2/11 (18.2%)
were KSCC, 7/11 (63.6%) were NK-D and 2/11 (18.2%)
were NK-U (Table 2, Figure 1). 9/11 (81.8%) and 2/11
(18.2%) of HPV positive NPCs occurred in Whites and
Blacks, respectively (Table 2, Figure 2). There were
no HPV positive NPCs in Far-eastern Asians (Table 2,
Figure 2). A statistically significant inverse correlation
Table 2 Summary of patient ethnicity and histological











n=9 n=47 n=11 n=0
Ethnicity
White 8 (88.9) 17 (36.2) 9 (81.8) 0 (0)
Far-Eastern Asian 1 (11.1) 16 (34.0) 0 (0) 0 (0)
Black 0 (0) 12 (25.5) 2 (18.2) 0 (0)
North African 0 (0) 2 (4.3) 0 (0) 0 (0)
Histological subtype
KSCC 3(33.3) 1 (2.1) 2 (18.2) 0 (0)
NK-D 4 (44.4) 9 (19.2) 7 (63.6) 0 (0)
NK-U 2 (22.2) 36 (76.6) 2 (18.2) 0 (0)

























Figure 2 Viral status of all NPC cases subdivided by ethnicity,
expressed as percentage.
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Asian ethnicity (both p<0.0001, Chi square). HPV-positive
NPCs were more likely to occur in Whites (p=0.03, Chi
square). Of the HPV-positive NPCs, 9/11 (81.8%) were ge-
notyped as HPV16, 1/11 (9.1%) was HPV18 and there was
insufficient amplifiable DNA in the remaining case.
Overall survival
Patients were followed up for a period of 4–120 months
(mean 33.7, median 26.0). The mean overall survival for
all cases was 63.1 months (95% CI 49.6-76.5) whereas
the mean overall survival for EBV-negative/HPV-negative,
EBV-positive/HPV-negative and EBV-negative/HPV-posi-























Figure 1 Viral status of NPCs by histological subtype of
keratinising squamous cell carcinoma (KSCC), non-keratinising
carcinoma, differentiated type (NK-D), non-keratinising
carcinoma, undifferentiated type (NK-U) and basaloid
squamous cell carcinoma (BSCC), expressed as percentage.(95% CI 52.1-83.7) and 53.6 months (95% CI 18.3-88.8), re-
spectively. There was no statistically significant difference
in the mean overall survival between EBV-negative/HPV-
negative, EBV-positive/HPV-negative and EBV-negative/
HPV-positive patients (p=0.57, log rank; Figure 3).
Discussion
Oncogenic HPV is now recognised as the causative fac-
tor for the striking increase in the incidence of cancers
of the oropharynx in recent decades in North America
and Western Europe. This phenomenon is accompa-
nied by the observation that patients with HPV-relatedFigure 3 Kaplan-Meier plot for overall survival of NPC by viral
status (EBV-/HPV-, EBV+/HPV- and EBV-/HPV+). There was no
statistically significant difference in the overall survival between
these groups (p=0.57, Log Rank).
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overall- and disease-specific survival compared to site-
matched HPV-negative cancers. Although HPV-related
head and neck cancers have a strong site predilection for
the oropharynx, the virus is also known to be associated
with carcinomas in other head and neck sites including
the nasopharynx [19]. However, while the biological be-
haviour of HPV-related oropharyngeal carcinoma is now
becoming increasingly established, little is known about
the clinical significance of this virus in NPC. This study
therefore aimed to address this knowledge gap by deter-
mining the incidence of oncogenic HPV in NPC and to
correlate viral status with patient ethnicity, histological
grade and overall survival.
There are morphological and functional similarities
between oro- and naso-pharyngeal mucosa. Both sites
contain mucosa-associated lymphoid tissue with reticu-
lar crypt epithelia that are specialised for trans-epithelial
antigen processing. These similarities, together with the
close anatomical proximity between these two sites have
led Singhi et al. to speculate that HPV-related carcin-
omas of the nasopharynx likely represent secondary
extension from the oropharynx [14]. Furthermore, since
all HPV-related nasopharyngeal tumours in their series
demonstrated oropharyngeal continuity, they maintain
confidence that detection of HPV in metastatic squa-
mous cell carcinomas in cervical nodes should direct
the search for the primary tumour to the oropharynx.
By contrast, in the current study, all tumours were
radiologically confirmed as centred in the nasopharynx
without any evidence of continuity with oropharyngeal
mucosa. The identification of HPV-related carcinomas
of truly nasopharyngeal origin raises the necessity of
including the nasopharyngeal mucosa in the search for
the primary tumour in patients presenting with HPV-
positive metastatic carcinomas from an unknown ori-
gin. Significantly, these data suggest that it may not be
oncologically safe to exclude the nasopharynx from the
field of therapeutic irradiation for these patients des-
pite the greater levels of toxicity.
The reported incidence of HPV in NPC ranges from
9–52.9% [8-10,12-14]. Although this wide range may be
attributed to differences in geographic variation with re-
gard to aetiology and prevalence of NPC, it is more likely
a result of non-standardised viral detection methods.
HPV DNA detection by PCR alone is known to result in
false positives [20,21] which explains why the incidence
of the virus in NPC is much lower when surrogate
markers for oncoprotein expression are used in combin-
ation with DNA in-situ hybridisation [14]. The current
study employed a previously described algorithm that
combines an initial screening using p16 immunohisto-
chemistry, a highly sensitive surrogate marker for viral
oncoprotein, followed by highly specific high-risk HPVDNA in-situ hybridisation [21]. This multi-tier approach
is likely therefore to represent a more accurate assess-
ment of the incidence of biologically significant onco-
genic HPV in NPC.
An increasing body of evidence now indicates that pa-
tients with HPV-positive oropharyngeal squamous cell
carcinoma have a better overall- and disease-specific sur-
vival compared to site-matched HPV-negative patients
[17]. However, little is known about the prognostic sig-
nificance HPV detection in non-oropharyngeal head and
neck cancer including those that arise within the naso-
pharynx. Since, to our knowledge, only a single report
has evaluated the clinical significance of HPV in this dis-
ease, we sought to correlate viral status with overall sur-
vival in our cohort of NPC patients [16]. We found no
significant difference in overall survival between patients
with HPV-positive and HPV-negative NPCs. Therefore,
unlike HPV-associated oropharyngeal carcinoma, the
oncogenic papillomavirus status in NPC is unlikely to in-
fluence survival outcome. These findings are timely since
there are now calls for treatment de-escalation for pa-
tients with HPV-positive oropharyngeal carcinoma based
on improved survival outcome. Our data suggest that
improved survival in HPV-positive tumours is likely to be
limited to the oropharyngeal carcinomas and there is
currently no evidence to support any changes in NPC
treatment protocols based on oncogenic HPV status. How-
ever, larger cohort studies are necessary to confirm the lack
of difference in survival outcome between HPV-positive
and HPV-negative NPC.
Evidence from UK-based studies indicates that 57-61%
of oropharyngeal carcinomas are attributable to high-risk
HPV [21,22]. Whilst data is emerging for the incidence
rates of HPV-associated cancer in non-oropharyngeal head
and neck sites, the current study is the first to provide such
data in NPC within an ethnically diverse UK population
[23]. The overall incidence of 16.4%, is in keeping
with other studies from Western centres using similar
detection methods [12,14]. Although these tumours are
rare in this population, our data suggest that NPC should
be included when evaluating the overall burden of HPV-
associated disease.
Our findings also confirm previous reports that HPV-
associated NPC is more likely, but not exclusively, to occur
in Whites [11]. The reason for the predilection of HPV in
this group of patients is unknown. Interestingly, while
some groups have identified HPV and EBV co-infection,
we and others demonstrate an inverse relationship between
these viruses such that all HPV-associated tumours do not
harbour EBV [8,11]. Our data support current guidelines
from the College of American Pathologists recommending
HPV testing in EBV-negative NPCs [24]. Although viral
status is unlikely to influence treatment decisions and out-
come, an accurate incidence and prevalence of oncogenic
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disease burden of HPV-related malignancy.
Conclusion
We confirm the presence of high-risk HPV in a subgroup
of NPC patients. HPV-16 is the most commonly impli-
cated genotype and prevalence of HPV-positive NPC is
16.4% in this UK population of mixed ethnicity. HPV-
associated NPC is more likely to occur in Whites, but there
is no association between histological grade and HPV sta-
tus in these tumours. Unlike HPV-related oropharyngeal
carcinoma, HPV status is not associated with improved
overall survival outcome in NPC. Larger cohort studies are
needed to confirm these findings and to characterise the
biological and clinical significance of HPV in NPC.
Methods
Ethics
This study has had National Research Ethics Service review
(12/SC/0151) and has been registered with National Health
Service Research and Development (RJ112/N247).
Patients and samples
Patients presenting to two UK head and neck cancer
centres (Guy’s and St. Thomas’ NHS Foundation Trust,
London and Newcastle-upon-Tyne Hospitals NHS Foun-
dation Trust) were identified retrospectively from path-
ology databases over a period of 12 years (2000–2012).Figure 4 An HPV-positive NPC. A-C. Representative photomicrograph
section of T2 STIR MRI image of the same patient. Arrows delineate tumourOnly tumours radiologically confirmed as centred in the
nasopharynx without extension into the oropharynx were
included in this study. Formalin-fixed paraffin embedded
(FFPE) tissue was available from 67 patients of which 48
were males and 19 females (M:F ratio 2.5:1) with a mean
age of 48 years (range 12–74 years old). There were 34
Whites (50.7%), 17 Far-Eastern Asians (25.4%), 14 Blacks
(20.9%), and two North Africans (3.0%). Patient and tu-
mour characteristic are summarised in Table 1.
All cases were independently classified according to
WHO histological criteria by two specialist head and
neck pathologists (MR and ST) [5]. A consensus was
reached for tumours with discordant grades. Ethnicity
and patient survival were determined by review of pa-
tient treatment records.
p16 immunohistochemistry
p16 immunohistochemistry (IHC) was performed on all
cases using a proprietary kit (CINtec Histology, mtm
Laboratories AG, Germany) on a Ventana Benchmark
Autostainer (Ventana Medical Systems Inc. USA). A ton-
sil carcinoma with high p16 expression was used as a
positive control. The primary antibody was omitted from
negative controls. The tests were independently scored
by two specialist head and neck pathologists (MR & ST)
using a binary scoring system and the recently described
H score (Figure 4) [18]. Discordant scores were resolved
by consensus at a meeting between the pathologists.s of H&E (A), p16 IHC (B) and high-risk HPV DNA ISH (C). D. Coronal
in the right nasopharynx.
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DNA was extracted from 25μm sections of FFPE biop-
sies using the QIAamp DNA (FFPE) tissue kit (Qiagen,
Crawley, UK) according to the manufacturer’s instruc-
tions. Contamination of samples with extrinsic DNA
was minimised by cleaning the microtome with xylene
and discarding the microtome blade between each case.
PCR reactions were carried out using standard operating
procedures to prevent sample contamination. All DNA
samples were screened for the human β-globin gene by
PCR to verify the presence of amplifiable DNA [25].
HPV DNA was analysed by PCR using the improved
general primer set GP5+/6+ which amplifies part of
the HPV L1 gene encoding the HPV major capsid pro-
tein, detecting low-risk genotypes −6, -11, -40, -42, -43
and −44 and high-risk genotypes −16, -18, -31,-33, -35,
-39, -45, -51, -52, -56, -58, -59, -66 and −68 as previ-
ously described [26]. DNA from the UPCI: SCC089
and SCC090 oropharyngeal squamous cell carcinoma
cell lines were used as positive and negative controls,
respectively [27]. A binary classification of presence or
absence of an amplicon of appropriate size on resolv-
ing gels was employed.
In-situ hybridisation
EBV RNA in-situ hybridisastion (ISH) was performed
using proprietary reagents (Inform EBER DNP RNA
probe, Ventana Medical Systems Inc, UK) on a Bench-
mark Autostainer (Ventana Medical Systems Inc. UK)
and visualised using the Ventana ISH/iView Blue detec-
tion kit according to manufacturer’s instructions. The
Inform EBER probe detects early RNA transcripts EBER-1
and EBER-2. Cells known to contain high numbers of
EBER transcripts were supplied by the manufacturer
and used as a positive control. An intense blue reaction
product in the majority of malignant cells was consid-
ered positive. The tests were independently scored by
the study pathologists using a binary classification and
a consensus agreement was reached for all discordant
scores.
All cases over-expressing p16 were subject to high-risk
HPV DNA ISH using proprietary reagents (Inform HPV
III Family 16 Probe (B), Ventana Medical Systems Inc,
USA) on a Benchmark Autostainer (Ventana Medical
Systems Inc. UK). The Inform HPV III Family 16 Probe
(B) detects high-risk genotypes HPV-16, -18, -31, -33, -35,
-39, -45,-51, -52, -56, -58 and −66. Three control samples
were used: FFPE CaSki cells (HPV-16-positive; 200–400
copies per cell), HeLa cells (HPV-18-positive; 10–50 copies
per cell) and C-33A (HPV-negative; Ventana Medical
Systems Inc. USA). The high-risk HPV ISH test was
scored as positive if there was any blue reaction product
that co-localised with cell nuclei. Diffuse nuclear and
cytoplasmic (‘episomal’ pattern) staining and punctatenuclear (‘integrated’ pattern) staining were scored as
positive (Figure 4). Focal specific staining of only part of
the tumour section was regarded as positive. Pale staining
limited to the nucleoli of cells and staining of occasional
leucocytes and stromal cells were also disregarded, in
line with the manufacturer’s instructions.
The tests were independently scored by the two study
pathologists using a binary classification as previously
described and a consensus agreement was reached for all
discordant scores [21]. Only cases demonstrating p16, PCR
and ISH positivity were considered as HPV-positive.
HPV genotype analysis
DNA was extracted from 10μm curls of formalin-fixed
paraffin embedded tissue using the Cobas DNA extraction
kit (Roche Molecular Systems Inc. USA). DNA yield was
measured using a Nanodrop spectrophotometer (Thermo
Scientific, USA). 200ng of DNA was diluted in 1000 μl of
Surepath fluid (BD Diagnostics-TriPath, USA) and the sam-
ples were analysed using the Cobas HPV test on the Cobas
4800 instrument (Roche Molecular Systems Inc. USA).
Statistical analysis
The Chi-squared test was used to evaluate the correlation
between different groups. Overall survival was defined as
the time from diagnosis to the date of death or last follow
up. The Kaplan-Meier method was used to estimate time
to event curves, and the survival curves were compared
using the log-rank test. P values below 0.05 were regarded
as significant. All data was analysed using SPSS software
version 20.
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